Clinical Trial Search

Primary: PTH (Parathyroid Hormone) Adherence — 0.23; 0.28 probability of having a PTH measured — p=0.04

Primary: Renal Failure Event Defined as Greater Than or Equal to 40% Decline in Estimated Glomerular Filtration Rate (eGFR) or Occurrence of End Stage Renal Disease (ESRD) — 9.7…

Primary: Number of Participants With CKD Diagnosis — 417; 389 Participants — p=.21

Primary: Mortality — 0; 0 percentage of mortality

Primary: Number of Participants With Treatment-related Adverse Events — 0 Participants

Primary: Incidence of Death From Any Cause or Myocardial Infarction — 123; 129 Participants

Primary: Change in Subjective Units of Distress Scale (SUDS) Score — 2.92; 3.12 score on a scale

Primary: Systolic Blood Pressure (SBP) — 135.1; 134.4 mmHg — p=0.57

Primary: Change in Peak Aerobic Capacity — 17.1; 16.8; 17.9; 15.9 ml/kg/min

Primary: Qualitative Survey Assessmentof Perceived Usefulness of the Med-alert Device. — 1 Likert scale

Primary: Difference in Mean CKD Register Patient eGFRs Between Groups After 3.5 Years of Study — -2.00; -2.29 mean average eGFR change/mL/min/1.73 m^2

Primary: Patient Activation Measure (PAM) -13 Item Questionnaire — 9.1; -1.4 points — p=0.01

Primary: Change is Leptin to Adiponectin Ratio (LAR) — 2.2; 1.3; 1.3; 1.4 ng/micrograms

Primary: Delta Curve Between Calculated GFR and GFR Measured by Iohexol at Baseline — 91.5; 88.3; 93.6; 90.0 ml/min/1.73m2 — p=<0.05

Primary: Safety Events — 70; 54; 61; 58 safety events

Primary: Percent Change From Baseline in Urinary Albumin-to-creatinine Ratio (ACR) — 3.2; 17.7; 5.4 Geometric Mean of Percent Change — p=0.485

Primary: Change From Baseline in eGFR at 3 Months (Patient-specific) — -1.71; -4.12 ml/min/1.73m^2

Primary: Phosphocreatine (PCR) Recovery Time After Knee Extension Assessed by 31 Phosphorus Magnetic Resonance Spectroscopy (31P-MRS) — 60.59; 62.66 seconds

Primary: Change in Brachial Artery Flow Mediated Dilation (FMD) — 1.1; -0.7 absolute change in percent FMD

Primary: Kidney Disease Quality of Life (KDQOL-36) Mean Scale Scores at Baseline, 6, 12 and 18 Months: Unadjusted — 35.5; 38.4; 36.3; 36.8 units on a scale

Primary: Percentage of Subjects Achieving an Increase in Hemoglobin of ≥1.0 g/dL at Any Time Point Between Baseline and the End of the 16-week Randomized Period — 61; 22…

Primary: The Patient Activation Measure (PAM) — 60.8; 61.5; 1.73; 3.44 score on a scale

Primary: Percentage of Participants Reaching a Hemoglobin (Hb) Value of Greater Than (>) 100 and Less Than (<) 120 Grams Per Liter (gm/L) at Month 6 Before Inclusion — 56.8…

Primary: Change in Baseline and 2 Week FMD/VP Measurements Between Sildenafil Group and Placebo Group — 10.8; 8.6 Change in FMD%

Primary: Number of Participants Achieving a Composite Endpoint of Initiation of Maintenance Dialysis or All-cause Mortality — 35; 46 Participants — p=.1602

Primary: Change in Blood Pressure — -1; -2; -2; -2 mmHg

Primary: Composite of Dialysis Initiation, Kidney Transplantation, and Serum Creatinine Doubling. Number of Participants Meeting the Criteria Are Reported. — 172; 183 participants

Primary: Mean Glucose Concentration Measured by CGM — 151.5 mg/dL

Primary: Mean Arterial Pressure-Middle Cerebral Artery Blood Velocity Very Low Frequency Phase (Radians) — 1.38; 1.12; 1.40; 1.60 Radians — p=0.05

Primary: Composite Global Cognitive Function — .15; .02 Z-score